CTI BioPharma CEO Investor Conference 2017

CTI BioPharma presented its hematology-focused pipeline at an investor conference, highlighting clinical programs including pacritinib for myelofibrosis, PIXUVRI for non-Hodgkin lymphoma, and tosedostat for acute myeloid leukemia. The presentation outlines the company's development strategy and regulatory pathway across Phase 2 and Phase 3 programs.